European Primary Care Cardiovascular Society

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD (Leipzig, Germany), prof. Chris Packard, PhD (Glasgow, UK) and prof. Wouter Jukema, MD, PhD (Leiden, The Netherlands)


Show transscript

Educational information

This discussion is part of a series titled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".


Prof. Ulrich Laufs, MD, PhD, is professor of cardiology at the University of Leipzig Medical Center in Germany.

Prof. Chris Packard, PhD, Research and Development Director, NHS Greater Glasgow & Clyde Health Board; Honorary professor of vascular biochemistry, University of Glasgow, Scotland, United Kingdom

Prof. J. Wouter Jukema, MD, PhD, is Professor of Cardiology at the Leiden University Medical Center in Leiden, The Netherlands.


This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.


Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

Watch the presentations of this symposium

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: